Market news

Prestige Consumer Healthcare has seen its share price under pressure over the past year, and that kind of slide naturally puts the spotlight on what investors are paying for its earnings today. The question now is whether the current valuation of Prestige Consumer Healthcare's profit stream still makes sense given how the business is executing. The stock has fallen 24.2% over the past year, which raises the issue of whether the current earnings multiple properly reflects what the company is...

Prestige Consumer Healthcare (PBH) recently outlined medium term targets for fiscal 2027, putting fresh attention on its over the counter portfolio, free cash flow priorities, and the impact of Clear Eyes supply constraints. Prestige Consumer Healthcare’s recent medium term outlook lands after a tougher stretch in the market, with the share price down 23.34% year to date and the 1 year total shareholder return declining 24.25%, while the 30 day share price return has fallen 10.56%. This...

Prestige Consumer Healthcare (NYSE:PBH) said its strategy centers on investing in established over-the-counter brands, maintaining a high-margin operating model and using free cash flow for debt reduction, acquisitions and other shareholder-value initiatives. Speaking at a fireside chat, Chief Fina

TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the followin

The voluntary recall of Clear Eyes Maximum Itchy Eye Relief affects 0.5-fluid-ounce bottles with the expiration date Sept. 30, 2027.

Detailed price information for Prestige Brand Holdings (PBH-N) from The Globe and Mail including charting and trades.

Nearly 40,000 bottles of Clear Eyes drops have been voluntarily pulled.

The recall affects 15mL bottles of Clear Eyes' Maximum Itchy Eye Relief.

Detailed price information for Prestige Brand Holdings (PBH-N) from The Globe and Mail including charting and trades.

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own targets even before Breathe Right and LaCorium Health joined the mix. […]

Motley Fool Press Release.

TARRYTOWN, N.Y., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Christine Sacco, CFO and COO, and Phil Terpolilli, VP, Investor Relations, Treasury, & Business Development will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday August 12, 2026 at 10:00 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Pr

Prestige Consumer Healthcare (NYSE:PBH) reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breat

Detailed price information for Prestige Brand Holdings (PBH-N) from The Globe and Mail including charting and trades.

Detailed price information for Prestige Brand Holdings (PBH-N) from The Globe and Mail including charting and trades.

Prestige Consumer Healthcare (PBH) shares were up 5% in early Thursday trading after the company rep

While the top- and bottom-line numbers for Prestige Consumer Healthcare (PBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of +10.11% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot

Q1 Revenue of $265.7 million up 6.5% versus prior yearQ1 Organic sales growth of 3.2%, exceeding expectationsQ1 Diluted EPS of $0.61; Adjusted Diluted EPS of $0.98, up versus prior year $0.95Q1 Cash from Operating Activities $70.8 million; Q1 Adjusted Non-GAAP Free Cash Flow of $83.7 millionClosed the Breathe Right® and LaCorium acquisitions in June and July, respectivelyRaising fiscal 2027 outlook to include acquisitions; anticipate revenue of $1,290 to $1,315 million and Adjusted Diluted EPS o

Detailed price information for Prestige Brand Holdings (PBH-N) from The Globe and Mail including charting and trades.

Investors need to pay close attention to PBH stock based on the movements in the options market lately.

TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026. Completion of LaCorium Health Acquisition The Company completed the acquisition on July 1, 2026. The closing was finalized pursuant to the terms of the de

Prestige Consumer Healthcare Inc. (NYSE:PBH) is one of the top stocks to buy according to Ariel Investments. On June 15, Prestige Consumer Healthcare Inc. (NYSE:PBH) completed the acquisition of the Breath Right brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion. The acquisition aligns with the company’s disciplined merger-and-acquisition framework and is […]